Effect of supplementation in treatment of polycystic ovary syndrome

Effects of vitamin D and calcium co-supplementation on inflammatory factors and biomarkers of oxidative stress in overweight and deficient vitamin D women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201407015623N21

Enrollment

104

Registered

2014-08-24

Start date

2014-05-22

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. Sclerocystic ovary syndrome Stein-Leventhal syndrome

Interventions

Intervention 1: Intervention group: Vitamin D pearl and calcium capsule, 50000 IU and 1000 mg, weekly and daily, for 8 weeks orally. Intervention 2: Intervention group: Vitamin D pearl, 50000 IU, week

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients with PCOS according to Rotterdam criteria Aged 18 to 40 years Overweight (BMI =25 kg/m2)

Exclusion criteria

Exclusion criteria: Pregnant or lactating women Taking medicinal treatment of infertility Individuals with diabetes mellitus Taking insulin-sensitizing agents and hormonal treatment involving oestrogen or progesterone within the last 3 months

Design outcomes

Primary

Measure	Time frame
HOMA-B. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.	—

Secondary

Measure	Time frame
Hs-CRP. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Elisa kit.;Plasma malondialdehyde. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Plasma total antioxidant capacity. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Catalase. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.	—

Measure

Time frame

Hs-CRP. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Elisa kit.;Plasma malondialdehyde. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Plasma total antioxidant capacity. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Catalase. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac+98 36 1446 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026